NEW YORK (GenomeWeb News) – Med BioGene today reported no revenues for the first quarter, the same as in the first quarter of 2012.

For the three months ended March 31, the Vancouver, British Columbia-based molecular diagnostics firm said the comprehensive loss totaled $74,133, or breakeven, compared to a loss of $120,701, or breakeven, a year ago, according to a document filed with Canadian regulators.

SG&A costs were lowered 35 percent to $78,414 from $121,296.

Med BioGene reported $291,717 in cash and cash equivalents at the end of the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.